Profund Advisors LLC Revance Therapeutics, Inc. Transaction History

Profund Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	SELL	$4.65 - $9.31 $73,851 - $147,861	-15,882 Reduced 41.15%	22,710 $111,000
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $21,096 - $40,667	3,631 Added 10.39%	38,592 $339,000
Q3 2023 Nov 13, 2023	BUY	$11.47 - $25.07 $187,591 - $410,019	16,355 Added 87.9%	34,961 $401,000
Q2 2023 Aug 10, 2023	BUY	$24.7 - $37.61 $39,149 - $59,611	1,585 Added 9.31%	18,606 $470,000
Q1 2023 May 11, 2023	BUY	$18.36 - $35.27 $312,505 - $600,330	17,021 New	17,021 $548,000
Q3 2021 Nov 12, 2021	SELL	$25.78 - $33.21 $179,016 - $230,610	-6,944 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$26.8 - $31.84 $186,099 - $221,096	6,944 New	6,944 $205,000
Q4 2018 Feb 14, 2019	SELL	$18.06 - $24.96 $201,260 - $278,154	-11,144 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$23.55 - $30.1 $262,441 - $335,434	11,144 New	11,144 $277,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Profund Advisors LLC with notifications on news.